Withdrawn × Neoplasms × Other hematologic neoplasm × Clear all DEC-C and Thioguanine for R/R AML
Phase 2 Withdrawn
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Phase 1 Withdrawn
A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review
Withdrawn
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
Phase 1/2 Withdrawn
Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
Phase 2 Withdrawn
Feasibility of Identifying a Chinese Study Population and Eligible Pediatric Cancer Cases, and Linking the Two Groups to Assess the Role of Periconceptional Folic Acid Supplements in Risk of Pediatric Cancer.
Withdrawn
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Phase 1 Withdrawn
Therapy for Progressive and/or Refractory Hematologic Malignancies
Phase 1/2 Withdrawn
Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
Phase 1 Withdrawn
Lenalidomide and Obinutuzumab for Previously Untreated CLL
Phase 2 Withdrawn
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1 Withdrawn
Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors
Phase NA Withdrawn
Acupuncture for Mucositis Pain in Cancer Care
Phase NA Withdrawn
Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)
Phase 1 Withdrawn
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
Phase NA Withdrawn